Empery Asset Management LP bought a new stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,863,115 shares of the company's stock, valued at approximately $2,855,228. Tenaya Therapeutics accounts for 0.0% of Empery Asset Management LP's portfolio, making the stock its 9th biggest holding. Empery Asset Management LP owned 1.72% of Tenaya Therapeutics as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently made changes to their positions in the stock. Comerica Bank purchased a new position in Tenaya Therapeutics during the 1st quarter valued at about $50,000. AQR Capital Management LLC purchased a new position in Tenaya Therapeutics in the 1st quarter valued at approximately $442,000. Woodline Partners LP boosted its holdings in Tenaya Therapeutics by 30,563.2% in the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after acquiring an additional 5,896,873 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Tenaya Therapeutics in the 2nd quarter worth about $90,000. Finally, Cerity Partners LLC increased its holdings in shares of Tenaya Therapeutics by 403.5% during the second quarter. Cerity Partners LLC now owns 110,336 shares of the company's stock valued at $67,000 after purchasing an additional 88,424 shares during the period. 90.54% of the stock is owned by hedge funds and other institutional investors.
Tenaya Therapeutics Price Performance
Shares of TNYA stock traded down $0.00 on Friday, hitting $0.69. The stock had a trading volume of 885,881 shares, compared to its average volume of 3,579,446. The company's 50 day moving average price is $0.76 and its 200-day moving average price is $0.75. The firm has a market capitalization of $155.46 million, a P/E ratio of -1.31 and a beta of 2.83. Tenaya Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.35.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.13). The company had revenue of $1.11 million for the quarter, compared to analysts' expectations of $10.00 million. On average, equities analysts forecast that Tenaya Therapeutics, Inc. will post -0.42 EPS for the current year.
Analyst Ratings Changes
TNYA has been the subject of several research analyst reports. Wall Street Zen downgraded Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 6th. Weiss Ratings raised Tenaya Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $4.00.
View Our Latest Report on TNYA
About Tenaya Therapeutics
(
Free Report)
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Recommended Stories
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Tenaya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenaya Therapeutics wasn't on the list.
While Tenaya Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
